Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Jasper Therapeutics, Inc. Market Cap
Based on ratings from 10 stock analysts, the Jasper Therapeutics, Inc. stock price is expected to increase by 209.16% in 12 months. This is calculated by using the average 12-month stock price forecast for Jasper Therapeutics, Inc.. The lowest target is $43 and the highest is $90. Please note analyst price targets are not guaranteed and could be missed completely.
Jasper Therapeutics, Inc. has a total of 10 Wall St Analyst ratings. There are 10 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Jasper Therapeutics, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of JSPR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Reiterates | Oct 24, 2024 |
| Silvan Tuerkcan JMP Securities | Market Outperform | $70 | Reiterates | Oct 15, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Reiterates | Oct 15, 2024 |
| Silvan Tuerkcan JMP Securities | Market Outperform | $70 | Reiterates | Sep 27, 2024 |
| Silvan Tuerkcan JMP Securities | Market Outperform | $70 | Initiates | Sep 9, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $65 | Maintains | Aug 26, 2024 |
| Gregory Renza RBC Capital | Outperform | $68 | Maintains | Aug 14, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Reiterates | Aug 13, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Reiterates | Aug 5, 2024 |
| Justin Zelin BTIG | Buy | $90 | Initiates | Jul 8, 2024 |
| Ben Burnett Stifel | Buy | $86 | Initiates | Jun 27, 2024 |
| Pete Stavropoulos Cantor Fitzgerald | Overweight | Reiterates | Jun 18, 2024 | |
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Reiterates | May 20, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Reiterates | May 15, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $65 | Initiates | May 6, 2024 |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $65 | Initiates | Apr 3, 2024 |
| Gregory Renza RBC Capital | Outperform | $70 | Initiates | Mar 28, 2024 |
| Yaron Werber TD Cowen | Outperform | Initiates | Mar 18, 2024 | |
| Jay Olson Oppenheimer | Outperform | $80 | Maintains | Mar 7, 2024 |
When did it IPO
2020
Staff Count
45
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Ronald A. Martell
Market Cap
$348.6M
In 2023, JSPR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that JSPR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Jasper Therapeutics has dosed the first patient in its Phase 1b/2a study for briquilimab, targeting allergic asthma. The study aims to assess the drug's efficacy and safety.
Why It Matters - Jasper Therapeutics' dosing of the first patient in a clinical trial for briquilimab signals potential advancements in treating allergic asthma, which could drive stock performance and market interest.
Mon, 18 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Jasper Therapeutics' Briquilimab shows potential for chronic urticaria and asthma treatment, with market approval possible by 2027. Financial risks loom, requiring funds by Q3 2025, potentially diluting shares. Analysts rate JSPR as a strong buy, target $69.5.
Why It Matters - Jasper Therapeutics' promising drug developments present potential high returns, but financial risks and funding needs could impact shareholder value and stock performance.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Jasper Therapeutics (Nasdaq: JSPR) will participate in upcoming investor conferences to discuss briquilimab, an antibody therapy for mast cell-driven diseases.
Why It Matters - Jasper Therapeutics' participation in investor conferences highlights its proactive approach to funding and visibility, which may attract investor interest and impact stock performance.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Jasper Therapeutics (Nasdaq: JSPR) reported Q3 2024 results, focusing on briquilimab for mast cell-driven diseases. The company also closed its legacy study in lower-risk myelodysplastic syndromes.
Why It Matters - Jasper Therapeutics’ quarterly results and closure of a legacy study indicate a strategic shift, impacting future growth potential and investor confidence in its novel therapies targeting mast cell diseases.
Thu, 24 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Jasper Therapeutics (Nasdaq: JSPR) is presenting preclinical data on briquilimab, an antibody therapy for mast cell diseases, at the ACAAI Annual Meeting from October 24-28, 2024.
Why It Matters - Jasper Therapeutics' presentation of briquilimab data at a major conference could impact stock performance, signaling potential advancements in treatment and investor confidence in clinical progress.
Mon, 14 Oct 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Jasper Therapeutics (JSPR) stock rises following preliminary data from its SPOTLIGHT Phase 1b/2a study of briquilimab for cold urticaria and symptomatic dermographism.
Why It Matters - Jasper Therapeutics' positive preliminary data can boost investor confidence, indicating potential market success for briquilimab and driving stock price up.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
